US FDA’s Current Technical Standards Not A Good Fit For Real-World Data, Stakeholders Say

The agency’s existing technical standards are better-suited to clinical trial data, and mapping RWD to these formats will result in the loss of granularity and introduce new opportunities for human error, pharmaceutical industry representatives and data companies say in comments on a draft guidance.

Shoehorn
FDA is trying to shoehord real-world data into existing, but unsuitable, technical standards, industry comments say. • Source: Alamy

The US Food and Drug Administration is trying to shoehorn real-world data into existing technical standards that are better-suited to clinical trial data, pharmaceutical industry stakeholders and data companies say.

In comments on the FDA’s draft guidance on data standards for drug submissions containing real-world data, stakeholders raise concerns about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Real-World Evidence

More from Clinical Trials